Literature DB >> 15213734

Effect of estrogen replacement treatment on ischemic preconditioning in isolated rat hearts.

Wei-Jie Peng1, Jing Yu, Sheng Deng, Jun-Ling Jiang, Han-Wu Deng, Yuan-Jian Li.   

Abstract

In the present study, we tested the effects of long-term estrogen replacement treatment on myocardial ischemia-reperfusion injury and on the cardioprotection of ischemic preconditioning in isolated hearts from ovariectomized rats. Ovariectomized rats were treated with 17beta-estradiol (30 micro g/kg/d, s.c.) for 12 weeks. Isolated rat hearts were perfused in the Langendorff mode. Heart rate, coronary flow, left ventricular pressure and its first derivative (+/-LVdp/dtmax) were recorded. Fifteen-min global ischemia and 30-min reperfusion caused a significant decrease of cardiac mechanical function, which were not affected by ovariectomy or estrogen replacement treatment. The isolated hearts in all groups could be preconditioned, and the cardioprotection afforded by preconditioning in the sham-operated rats was greater compared with ovariectomized rats with or without estrogen treatment. These results suggest that long-term estrogen replacement treatment exerts no effect on the inhibition of mechanical function after ischemia-reperfusion, and this study also suggests that estrogen does not affect ischemic preconditioning in isolated hearts of ovariectomized rats.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213734     DOI: 10.1139/y04-024

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  2 in total

1.  The role of 17-beta estradiol in ischemic preconditioning protection of the heart.

Authors:  Fawzi A Babiker; Lamia J Hoteit; Shaji Joseph; Abu Salim Mustafa; Jasbir S Juggi
Journal:  Exp Clin Cardiol       Date:  2012-09

2.  Loss of ischaemic preconditioning in ovariectomized rat hearts: possible involvement of impaired protein kinase C epsilon phosphorylation.

Authors:  Ken Shinmura; Maiko Nagai; Kayoko Tamaki; Roberto Bolli
Journal:  Cardiovasc Res       Date:  2008-04-04       Impact factor: 10.787

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.